{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:57:03Z","timestamp":1781647023333,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic kidney disease (CKD) is a major global health concern driven by hypertension and diabetes, with genetic factors playing a key role in its pathogenesis. CX3CR1, the sole known receptor for the chemokine fractalkine, and its polymorphisms T280M and V249I have been implicated in the progression of several chronic diseases. This prospective observational study investigates the role of the CX3CR1 T280M polymorphism in CKD progression to end-stage disease. We included 121 CKD patients with varying renal insufficiency severity. Patients were stratified by CX3CR1-T280M genotype: Group 1 wild-type (T\/T, 71.9%) and Group 2 carriers of the mutated allele (T\/M or M\/M, 28.1%). The primary outcome was kidney replacement therapy (KRT) initiation over 18 years. Cox proportional hazards univariate analysis was used for survival assessment. The M allele for CX3CR1 is associated with higher baseline serum creatinine levels, consistent with previous cross-sectional studies. During follow-up, KRT was initiated in 26 patients (17.2% in Group 1, 32.3% in Group 2). Survival analysis showed a significant association between the CX3CR1-T280M polymorphism and CKD progression (HR 2.28, 95% CI: 1.04\u20134.98, p 0.039). This study confirms the role of the CX3CR1-T280M polymorphism in determining prognosis in CKD patients, particularly in predicting the risk of a critical outcome such as initiation of KRT.<\/jats:p>","DOI":"10.1038\/s41598-026-40013-8","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:13:20Z","timestamp":1775207600000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CX3CR1-T280M polymorphism and end-stage renal disease development in chronic kidney disease"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9556-5391","authenticated-orcid":false,"given":"Matteo","family":"Gatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivano","family":"Baragetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Baragetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Buzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Fassio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Olmastroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fabbrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"issue":"10","key":"40013_CR1","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1007\/s12325-023-02608-9","volume":"40","author":"V Jha","year":"2023","unstructured":"Jha, V. et al. Global economic burden associated with chronic kidney disease: A pragmatic review of medical costs for the inside CKD research programme. Adv. Ther. 40 (10), 4405\u20134420. https:\/\/doi.org\/10.1007\/s12325-023-02608-9 (2023).","journal-title":"Adv. Ther."},{"issue":"18","key":"40013_CR2","doi-asserted-by":"publisher","first-page":"10084","DOI":"10.3390\/ijms221810084","volume":"22","author":"MT Yan","year":"2021","unstructured":"Yan, M. T., Chao, C. T. & Lin, S. H. Chronic kidney disease: strategies to retard progression. Int. J. Mol. Sci. 22 (18), 10084. https:\/\/doi.org\/10.3390\/ijms221810084 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"40013_CR3","doi-asserted-by":"crossref","unstructured":"Exploring the impact and utility of genomic sequencing in established CKD | Clinical Kidney Journal | Oxford Academic. Accessed August 7. (2024). https:\/\/academic.oup.com\/ckj\/article\/17\/3\/sfae043\/7612242","DOI":"10.1093\/ckj\/sfae043"},{"issue":"12","key":"40013_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cells12121581","volume":"12","author":"SP Kadatane","year":"2023","unstructured":"Kadatane, S. P., Satariano, M., Massey, M., Mongan, K. & Raina, R. The role of inflammation in CKD. Cells 12 (12), 12. https:\/\/doi.org\/10.3390\/cells12121581 (2023).","journal-title":"Cells"},{"issue":"1","key":"40013_CR5","doi-asserted-by":"publisher","first-page":"2180373","DOI":"10.1155\/2018\/2180373","volume":"2018","author":"S Mihai","year":"2018","unstructured":"Mihai, S. et al. Inflammation-Related mechanisms in chronic kidney disease Prediction, Progression, and outcome. J. Immunol. Res. 2018 (1), 2180373. https:\/\/doi.org\/10.1155\/2018\/2180373 (2018).","journal-title":"J. Immunol. Res."},{"issue":"16","key":"40013_CR6","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1111\/febs.14466","volume":"285","author":"CE Hughes","year":"2018","unstructured":"Hughes, C. E. & Nibbs, R. J. B. A guide to chemokines and their receptors. FEBS J. 285 (16), 2944\u20132971. https:\/\/doi.org\/10.1111\/febs.14466 (2018).","journal-title":"FEBS J."},{"key":"40013_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/978-3-319-07320-0_14","volume":"824","author":"A Gugliucci","year":"2014","unstructured":"Gugliucci, A. & Menini, T. The axis AGE-RAGE-soluble RAGE and oxidative stress in chronic kidney disease. Adv. Exp. Med. Biol. 824, 191\u2013208. https:\/\/doi.org\/10.1007\/978-3-319-07320-0_14 (2014).","journal-title":"Adv. Exp. Med. Biol."},{"issue":"6","key":"40013_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrneph.2010.54","volume":"6","author":"V D\u2019Agati","year":"2010","unstructured":"D\u2019Agati, V. & Schmidt, A. M. RAGE and the pathogenesis of chronic kidney disease. Nat. Rev. Nephrol. 6 (6), 352\u2013360. https:\/\/doi.org\/10.1038\/nrneph.2010.54 (2010).","journal-title":"Nat. Rev. Nephrol."},{"issue":"4","key":"40013_CR9","doi-asserted-by":"publisher","first-page":"e60089","DOI":"10.1371\/journal.pone.0060089","volume":"8","author":"I Baragetti","year":"2013","unstructured":"Baragetti, I. et al. -374 T\/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by nephrocardiovascular disease. PLoS One. 8 (4), e60089. https:\/\/doi.org\/10.1371\/journal.pone.0060089 (2013).","journal-title":"PLoS One"},{"issue":"6617","key":"40013_CR10","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/385640a0","volume":"385","author":"JF Bazan","year":"1997","unstructured":"Bazan, J. F. et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 385 (6617), 640\u2013644. https:\/\/doi.org\/10.1038\/385640a0 (1997).","journal-title":"Nature"},{"key":"40013_CR11","unstructured":"Neurotactin a membrane-anchored chemokine upregulated in brain inflammation | Nature. Accessed August 7, (2024). https:\/\/www.nature.com\/articles\/42491"},{"issue":"4","key":"40013_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0092-8674(00)80438-9","volume":"91","author":"T Imai","year":"1997","unstructured":"Imai, T. et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91 (4), 521\u2013530. https:\/\/doi.org\/10.1016\/S0092-8674(00)80438-9 (1997).","journal-title":"Cell"},{"issue":"1","key":"40013_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1365-2567.2011.03409.x","volume":"133","author":"I Hamann","year":"2011","unstructured":"Hamann, I. et al. Analyses of phenotypic and functional characteristics of CX3CR1-expressing natural killer cells. Immunology 133 (1), 62\u201373. https:\/\/doi.org\/10.1111\/j.1365-2567.2011.03409.x (2011).","journal-title":"Immunology"},{"issue":"1","key":"40013_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/1521-4141","volume":"30","author":"A Foussat","year":"2000","unstructured":"Foussat, A. et al. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur. J. Immunol. 30 (1), 87\u201397. https:\/\/doi.org\/10.1002\/1521-4141 (2000). :1%3C87::AID-IMMU87%3E3.0.CO;2-7.","journal-title":"Eur. J. Immunol."},{"issue":"11","key":"40013_CR15","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/nm.2253","volume":"16","author":"C Mionnet","year":"2010","unstructured":"Mionnet, C. et al. CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung. Nat. Med. 16 (11), 1305\u20131312. https:\/\/doi.org\/10.1038\/nm.2253 (2010).","journal-title":"Nat. Med."},{"issue":"1","key":"40013_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S1074-7613(03)00174-2","volume":"19","author":"F Geissmann","year":"2003","unstructured":"Geissmann, F., Jung, S. & Littman, D. R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19 (1), 71\u201382. https:\/\/doi.org\/10.1016\/S1074-7613(03)00174-2 (2003).","journal-title":"Immunity"},{"issue":"11","key":"40013_CR17","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1128\/MCB.20.11.4106-4114.2000","volume":"20","author":"S Jung","year":"2000","unstructured":"Jung, S. et al. Analysis of fractalkine receptor CX3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 20 (11), 4106\u20134114. https:\/\/doi.org\/10.1128\/MCB.20.11.4106-4114.2000 (2000).","journal-title":"Mol. Cell. Biol."},{"issue":"1","key":"40013_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/path.1010","volume":"196","author":"P Cockwell","year":"2002","unstructured":"Cockwell, P., Chakravorty, S. J., Girdlestone, J. & Savage, C. O. S. Fractalkine expression in human renal inflammation. J. Pathol. 196 (1), 85\u201390. https:\/\/doi.org\/10.1002\/path.1010 (2002).","journal-title":"J. Pathol."},{"issue":"2","key":"40013_CR19","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1046\/j.1523-1755.2002.00480.x","volume":"62","author":"S Segerer","year":"2002","unstructured":"Segerer, S. et al. Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney Int. 62 (2), 488\u2013495. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00480.x (2002).","journal-title":"Kidney Int."},{"issue":"4","key":"40013_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00011-010-0284-3","volume":"60","author":"M Borkar","year":"2011","unstructured":"Borkar, M., Tripathi, G., Sharma, R. K., Sankhwar, S. N. & Agrawal, S. Chemokine (CCR) and fractalkine (CX3CR) receptors and end stage renal disease. Inflamm. Res. 60 (4), 399\u2013407. https:\/\/doi.org\/10.1007\/s00011-010-0284-3 (2011).","journal-title":"Inflamm. Res."},{"issue":"5461","key":"40013_CR21","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1126\/science.287.5461.2274","volume":"287","author":"S Faure","year":"2000","unstructured":"Faure, S. et al. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 287 (5461), 2274\u20132277. https:\/\/doi.org\/10.1126\/science.287.5461.2274 (2000).","journal-title":"Science"},{"issue":"8","key":"40013_CR22","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1172\/JCI16790","volume":"111","author":"DH McDermott","year":"2003","unstructured":"McDermott, D. H. et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J. Clin. Invest. 111 (8), 1241\u20131250. https:\/\/doi.org\/10.1172\/JCI16790 (2003).","journal-title":"J. Clin. Invest."},{"issue":"5","key":"40013_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","volume":"63","author":"LA Inker","year":"2014","unstructured":"Inker, L. A. et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am. J. Kidney Dis. 63 (5), 713\u2013735. https:\/\/doi.org\/10.1053\/j.ajkd.2014.01.416 (2014).","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"40013_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/M13-2453","volume":"160","author":"M Tonelli","year":"2014","unstructured":"Tonelli, M., Wanner, C. & Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline. Ann. Intern. Med. 160 (3), 182. https:\/\/doi.org\/10.7326\/M13-2453 (2014).","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"40013_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.4103\/0971-4065.163426","volume":"26","author":"AK Yadav","year":"2016","unstructured":"Yadav, A. K., Kumar, V. & Jha, V. Association of chemokine receptor CX3CR1 V249I and T280M polymorphisms with chronic kidney disease. Indian J. Nephrol. 26 (4), 275\u2013279. https:\/\/doi.org\/10.4103\/0971-4065.163426 (2016).","journal-title":"Indian J. Nephrol."},{"key":"40013_CR26","doi-asserted-by":"publisher","first-page":"6634365","DOI":"10.1155\/2021\/6634365","volume":"2021","author":"AF Ibrahim","year":"2021","unstructured":"Ibrahim, A. F. et al. CX3CR1 at V249M and T280M gene polymorphism and its potential risk for End-Stage renal diseases in Egyptian patients. Int. J. Nephrol. 2021, 6634365. https:\/\/doi.org\/10.1155\/2021\/6634365 (2021).","journal-title":"Int. J. Nephrol."},{"issue":"7","key":"40013_CR27","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1182\/blood.v97.7.1925","volume":"97","author":"D Moatti","year":"2001","unstructured":"Moatti, D. et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 97 (7), 1925\u20131928. https:\/\/doi.org\/10.1182\/blood.v97.7.1925 (2001).","journal-title":"Blood"},{"issue":"5","key":"40013_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1161\/hh1701.095642","volume":"89","author":"DH McDermott","year":"2001","unstructured":"McDermott, D. H. et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ. Res. 89 (5), 401\u2013407. https:\/\/doi.org\/10.1161\/hh1701.095642 (2001).","journal-title":"Circ. Res."},{"issue":"6","key":"40013_CR29","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1161\/01.STR.0000128528.56009.d4","volume":"35","author":"G Ghilardi","year":"2004","unstructured":"Ghilardi, G., Biondi, M. L., Turri, O., Guagnellini, E. & Scorza, R. Internal carotid artery occlusive disease and polymorphisms of fractalkine receptor CX3CR1: a genetic risk factor. Stroke 35 (6), 1276\u20131279. https:\/\/doi.org\/10.1161\/01.STR.0000128528.56009.d4 (2004).","journal-title":"Stroke"},{"issue":"6","key":"40013_CR30","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1161\/01.STR.0000221803.16897.22","volume":"37","author":"GD Norata","year":"2006","unstructured":"Norata, G. D. et al. Effects of fractalkine receptor variants on common carotid artery intima-media thickness. Stroke 37 (6), 1558\u20131561. https:\/\/doi.org\/10.1161\/01.STR.0000221803.16897.22 (2006).","journal-title":"Stroke"},{"issue":"2","key":"40013_CR31","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/s0021-9150(02)00362-3","volume":"166","author":"A Gugl","year":"2003","unstructured":"Gugl, A. et al. Two polymorphisms in the Fracalkine receptor CX3CR1 are not associated with peripheral arterial disease. Atherosclerosis 166 (2), 339\u2013343. https:\/\/doi.org\/10.1016\/s0021-9150(02)00362-3 (2003).","journal-title":"Atherosclerosis"},{"issue":"4","key":"40013_CR32","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1161\/01.ATV.0000157150.23641.36","volume":"25","author":"E Lavergne","year":"2005","unstructured":"Lavergne, E. et al. Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. Arterioscler. Thromb. Vasc Biol. 25 (4), 847\u2013853. https:\/\/doi.org\/10.1161\/01.ATV.0000157150.23641.36 (2005).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"issue":"2","key":"40013_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ymgme.2005.02.010","volume":"85","author":"KG dos Santos","year":"2005","unstructured":"dos Santos, K. G. et al. The \u2013\u2009374A allele of the receptor for advanced glycation end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with type 2 diabetes. Mol. Genet. Metab. 85 (2), 149\u2013156. https:\/\/doi.org\/10.1016\/j.ymgme.2005.02.010 (2005).","journal-title":"Mol. Genet. Metab."},{"issue":"11","key":"40013_CR34","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1007\/s00125-006-0412-3","volume":"49","author":"E Lindholm","year":"2006","unstructured":"Lindholm, E. et al. The \u2013\u2009374 T\/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients. Diabetologia 49 (11), 2745\u20132755. https:\/\/doi.org\/10.1007\/s00125-006-0412-3 (2006).","journal-title":"Diabetologia"},{"issue":"1","key":"40013_CR35","first-page":"95","volume":"16","author":"HA Abdel-Azeez","year":"2009","unstructured":"Abdel-Azeez, H. A. & El-Okely, A. M. Association of the receptor for advanced glycation end products (RAGE) -374 T\/A gene polymorphism and Circulating soluble RAGE with nephropathy in type 1 diabetic patients. Egypt. J. Immunol. 16 (1), 95\u2013106 (2009).","journal-title":"Egypt. J. Immunol."},{"issue":"1","key":"40013_CR36","doi-asserted-by":"publisher","first-page":"10165","DOI":"10.1038\/s41598-021-89442-7","volume":"11","author":"T Waas","year":"2021","unstructured":"Waas, T. et al. Distribution of estimated glomerular filtration rate and determinants of its age dependent loss in a German population-based study. Sci. Rep. 11 (1), 10165. https:\/\/doi.org\/10.1038\/s41598-021-89442-7 (2021).","journal-title":"Sci. Rep."},{"key":"40013_CR37","doi-asserted-by":"publisher","unstructured":"Cormican, S. & Griffin, M. D. Fractalkine (CX3CL1) and its receptor CX3CR1: A promising therapeutic target in chronic kidney disease? Front. Immunol. 12 https:\/\/doi.org\/10.3389\/fimmu.2021.664202 (2021).","DOI":"10.3389\/fimmu.2021.664202"},{"issue":"5","key":"40013_CR38","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/sj.ki.5002368","volume":"72","author":"MJ Koziolek","year":"2007","unstructured":"Koziolek, M. J. et al. Potential role of fractalkine receptor expression in human renal fibrogenesis. Kidney Int. 72 (5), 599\u2013607. https:\/\/doi.org\/10.1038\/sj.ki.5002368 (2007).","journal-title":"Kidney Int."},{"issue":"3","key":"40013_CR39","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/sj.ki.5001567","volume":"70","author":"TJ Soos","year":"2006","unstructured":"Soos, T. J. et al. CX3CR1\u2009+\u2009interstitial dendritic cells form a contiguous network throughout the entire kidney. Kidney Int. 70 (3), 591\u2013596. https:\/\/doi.org\/10.1038\/sj.ki.5001567 (2006).","journal-title":"Kidney Int."},{"issue":"10","key":"40013_CR40","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1172\/JCI70143","volume":"123","author":"K Hochheiser","year":"2013","unstructured":"Hochheiser, K. et al. Exclusive CX3CR1 dependence of kidney DCs impacts glomerulonephritis progression. J. Clin. Invest. 123 (10), 4242\u20134254. https:\/\/doi.org\/10.1172\/JCI70143 (2013).","journal-title":"J. Clin. Invest."},{"issue":"6460","key":"40013_CR41","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.aat5031","volume":"365","author":"BJ Stewart","year":"2019","unstructured":"Stewart, B. J. et al. Spatiotemporal immune zonation of the human kidney. Science 365 (6460), 1461\u20131466. https:\/\/doi.org\/10.1126\/science.aat5031 (2019).","journal-title":"Science"},{"key":"40013_CR42","doi-asserted-by":"publisher","unstructured":"Collar, A. L. et al. The homozygous CX3CR1-M280 mutation impairs human monocyte survival. JCI Insight. 3 (3). https:\/\/doi.org\/10.1172\/jci.insight.95417 (2018).","DOI":"10.1172\/jci.insight.95417"},{"issue":"19","key":"40013_CR43","doi-asserted-by":"publisher","first-page":"19649","DOI":"10.1074\/jbc.M313457200","volume":"279","author":"M Daoudi","year":"2004","unstructured":"Daoudi, M. et al. Enhanced adhesive capacities of the naturally occurring Ile249-Met280 variant of the chemokine receptor CX3CR1. J. Biol. Chem. 279 (19), 19649\u201319657. https:\/\/doi.org\/10.1074\/jbc.M313457200 (2004).","journal-title":"J. Biol. Chem."},{"issue":"7","key":"40013_CR44","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/imcb.12032","volume":"96","author":"EP Connaughton","year":"2018","unstructured":"Connaughton, E. P. et al. Phenotypic and functional heterogeneity of human intermediate monocytes based on HLA-DR expression. Immunol. Cell. Biology. 96 (7), 742\u2013758. https:\/\/doi.org\/10.1111\/imcb.12032 (2018).","journal-title":"Immunol. Cell. Biology"},{"issue":"5","key":"40013_CR45","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1681\/ASN.0000000000000083","volume":"34","author":"S Cormican","year":"2023","unstructured":"Cormican, S. et al. Chronic kidney disease is characterized by expansion of a distinct Proinflammatory intermediate monocyte subtype and by increased monocyte adhesion to endothelial cells. J. Am. Soc. Nephrol. 34 (5), 793. https:\/\/doi.org\/10.1681\/ASN.0000000000000083 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"7","key":"40013_CR46","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1161\/STROKEAHA.118.024692","volume":"50","author":"E Olmastroni","year":"2019","unstructured":"Olmastroni, E. et al. Multilevel models to estimate carotid Intima-Media thickness curves for individual cardiovascular risk evaluation. Stroke 50 (7), 1758\u20131765. https:\/\/doi.org\/10.1161\/STROKEAHA.118.024692 (2019).","journal-title":"Stroke"},{"key":"40013_CR47","unstructured":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease - Kidney International. Accessed August 7. (2024). https:\/\/www.kidney-international.org\/article\/S0085-2538(23)00766-4\/fulltext"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40013-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40013-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40013-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:27:06Z","timestamp":1781645226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40013-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["40013"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-40013-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AL.C. has received honoraria, lecture fees, or research grants from: Amarin, Amgen, Amryt Pharma, Astrazeneca, Daiichi Sankyo, Esperion, Eli Lilly, Ionis Pharmaceutical, Medscape, Menarini, Merck, Novartis, NovoNordisk, Peervoice, Pfizer, Recordati, Regeneron, Sandoz, Sanofi, The Corpus, Ultragenyx, Viatris.\u00a0A.B. reports honoraria from Novartis and stock options from BlackRock (BGF World Healthscience Fund).\u00a0All other authors declare that they do not have any competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15949"}}